Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report)'s share price was up 4.4% during mid-day trading on Tuesday . The stock traded as high as $33.81 and last traded at $34.34. Approximately 295,438 shares traded hands during trading, a decline of 76% from the average daily volume of 1,231,959 shares. The stock had previously closed at $32.90.
Analyst Ratings Changes
A number of analysts have issued reports on PCVX shares. The Goldman Sachs Group lowered their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Bank of America dropped their price target on Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Needham & Company LLC reissued a "buy" rating and issued a $90.00 price objective on shares of Vaxcyte in a report on Tuesday, April 8th. Cantor Fitzgerald assumed coverage on shares of Vaxcyte in a report on Tuesday, April 22nd. They issued an "overweight" rating on the stock. Finally, Guggenheim reissued a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $136.50.
View Our Latest Analysis on PCVX
Vaxcyte Stock Up 5.5 %
The stock has a market capitalization of $4.47 billion, a P/E ratio of -7.54 and a beta of 1.26. The company has a fifty day moving average price of $54.56 and a 200-day moving average price of $79.33.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.14. As a group, research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.
Insider Transactions at Vaxcyte
In related news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the transaction, the chief operating officer now owns 154,931 shares in the company, valued at approximately $11,351,794.37. The trade was a 4.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 24,000 shares of company stock valued at $1,946,720 in the last three months. 3.10% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Vaxcyte
Several hedge funds have recently modified their holdings of the stock. Whipplewood Advisors LLC acquired a new stake in Vaxcyte in the 4th quarter valued at about $28,000. Smartleaf Asset Management LLC boosted its position in shares of Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after buying an additional 260 shares during the period. National Bank of Canada FI acquired a new stake in shares of Vaxcyte during the fourth quarter valued at about $41,000. Blue Trust Inc. increased its holdings in Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after buying an additional 371 shares during the last quarter. Finally, Assetmark Inc. grew its holdings in shares of Vaxcyte by 77,500.0% during the fourth quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after purchasing an additional 775 shares during the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.
Vaxcyte Company Profile
(
Get Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
